Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

NCT04101357 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Solid Tumor
Extensive-stage Small Cell Lung Cancer

Interventions

DRUG: BNT411
DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

BioNTech SE